1. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
- Author
-
Inzinger M, Wippel-Slupetzky K, Weger W, Richter L, Mlynek A, Fleischander B, Scheurecker C, Sandor N, Mairhofer D, Sator PG, Moser-Oberthaler S, Häring N, Viznerova P, Painsi C, Tanew A, Ponholzer P, Tatarski R, Brenner W, Stingl G, Salmhofer W, Rappersberger K, Klein G, Saxinger W, Auböck J, Kölli C, Trautinger F, Steiner A, Ratzinger G, Strohal R, Riedl E, Lange-Asschenfeldt B, Pehamberger H, Volc-Platzer B, Selhofer S, Legat FJ, Müllegger R, Reider N, Schmuth M, Hintner H, Hofer A, Gruber-Wackernagel A, Aberer W, Quehenberger F, and Wolf P
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Austria, Biological Products adverse effects, Female, Humans, Immunosuppressive Agents adverse effects, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Psoriasis diagnosis, Psoriasis immunology, Registries, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha immunology, Young Adult, Activities of Daily Living, Biological Products therapeutic use, Immunosuppressive Agents therapeutic use, Psoriasis drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
- Published
- 2016
- Full Text
- View/download PDF